XML 29 R17.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Stock Compensation Plans | 3 Months Ended
--- | ---
Dec. 31, 2024
Share-Based Payment Arrangement, Noncash Expense [Abstract] |
Stock Compensation Plans | STOCK COMPENSATION PLANS The Company has two active stock compensation plans: the 2014 Equity Incentive Plan and the 2019 Equity Incentive Plan. Under the Company's 2014 Equity Incentive Plan, the Company may grant options and awards of restricted stock (with or without performance measures) for up to 352,366 shares of common stock to employees, officers, directors and directors emeriti. Under the Company's 2019 Equity Incentive Plan, the Company may grant options and awards of restricted stock (with or without performance measures) for up to 350,000 shares of common stock, of which 300,000 shares are reserved to be awarded to employees and officers, and 50,000 shares are reserved to be awarded to directors and directors emeriti. Shares issued may be purchased in the open market or may be issued from authorized and unissued shares. The exercise price of each option equals the fair market value of the Company’s common stock on the date of grant. Generally, options and restricted stock vest in equal annual installments commencing on the first anniversary of the grant date. Stock options generally vest over a five year period from the date of the grant with a maximum contractual term of ten years from the date of grant. Restricted stock grants generally vest over a three or five year term from the grant date. At December 31, 2024, there were 15,576 and 155,705 shares of common stock available which may be awarded as options or restricted stock pursuant to future grants under the 2014 and 2019 Equity Incentive Plans, respectively. Stock option activity for the three months ended December 31, 2024 and 2023 is summarized as follows:
| Three Months Ended December 31, 2024 |  | Three Months Ended December 31, 2023
| Number of Shares |  | Weighted Average Exercise Price |  | Number of Shares |  | Weighted Average Exercise Price
Options outstanding, beginning of period | 306,240 |  |  | $ | 25.21 |  |  | 369,150 |  |  | $ | 24.00 |
Exercised | (22,400) |  |  | 21.17 |  |  | (27,700) |  |  | 12.81 |
Forfeited | (600) |  |  | 27.40 |  |  | (5,380) |  |  | 25.10 |
Options outstanding, end of period | 283,240 |  |  | $ | 25.52 |  |  | 336,070 |  |  | $ | 24.91 |
The fair value of stock options is determined using the Black-Scholes valuation model. There were no stock options granted during the three months ended December 31, 2024 and 2023.
The aggregate intrinsic value of options exercised during the three months ended December 31, 2024 and 2023 was $239,000 and $469,000, respectively. At December 31, 2024, there were 76,530 unvested options with an aggregate grant date fair value of $464,000, all of which the Company assumes will vest. The aggregate intrinsic value of unvested options at December 31, 2024 was $328,000. There were 100 options that vested during the three months ended December 31, 2024 with a total fair value of $326. At December 31, 2023, there were 124,640 unvested options with an aggregate grant date fair value of $725,000. There were 100 options that vested during the three months ended December 31, 2023 with a total fair value of $326.
Additional information regarding options outstanding at December 31, 2024 is as follows:
|  |  |  | Options Outstanding |  | Options Exercisable
Range of Exercise Prices ($) |  | Number |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life (Years) |  | Number |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life (Years)
10.26 | - | 10.71 |  | 14,750 |  |  | $ | 10.62 |  |  | 0.5 |  | 14,750 |  |  | $ | 10.62 |  |  | 0.5
15.67 | - | 19.13 |  | 50,750 |  |  | 16.57 |  |  | 4.7 |  | 39,920 |  |  | 16.48 |  |  | 4.5
26.50 | - | 27.40 |  | 91,020 |  |  | 27.32 |  |  | 6.9 |  | 51,720 |  |  | 27.25 |  |  | 6.1
28.23 | - | 29.69 |  | 95,400 |  |  | 28.80 |  |  | 5.2 |  | 69,800 |  |  | 29.01 |  |  | 4.6
31.80 | - | 33.40 |  | 31,320 |  |  | 31.85 |  |  | 3.9 |  | 30,520 |  |  | 31.59 |  |  | 3.8
|  |  |  | 283,240 |  |  | $ | 25.52 |  |  | 5.3 |  | 206,710 |  |  | $ | 25.25 |  |  | 4.5
The aggregate intrinsic value of options outstanding at December 31, 2024 and 2023 was $1.45 million and $2.22 million, respectively. As of December 31, 2024, unrecognized compensation cost related to unvested stock options was $437,000, which is expected to be recognized over a weighted average period of 1.60 years. There were no restricted stock awards granted during the three months ended December 31, 2024 and 2023.
|  | Three Months Ended December 31, 2024 |  | Three Months Ended December 31, 2023
|  | Number of Unvested Shares |  | Weighted Average Grant Date Fair Value |  | Number of Unvested Shares |  | Weighted Average Grant Date Fair Value
Restricted stock outstanding beginning of period |  | 49,015 |  |  | $ | 29.28 |  |  | 26,150 |  |  | $ | 27.37 |
Forfeited |  | (450) |  |  | 29.28 |  |  | — |  |  | — |
Restricted stock outstanding end of period |  | 48,565 |  |  | $ | 29.28 |  |  | 26,150 |  |  | $ | 27.37 |
The fair value of restricted stock awards is equal to the fair value of the Company's stock on the date of the grant. The related stock-based compensation expense is recorded over the requisite service period. At December 31, 2024, unrecognized compensation cost related to unvested restricted stock awards was $1.34 million, which is expected to be recognized over a weighted average period of 2.45 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration